Drug Discovery & Development - Virtual Event Agenda

Predicting Protein Structure, Ligand Binding and Receptor Selectivity on GPCRs
Hugo Gutierrez de Teran, Senior Researcher, Uppsala University, Sweden

G-protein coupled receptors (GPCRs) are one of the main target families in pharmaceutical research. We will present our computational pipeline to assist ligand design and receptor characterisation and show applications in different projects, where we collaborate with medicinal chemists, neuropharmacologists from the academy, as well as some pharmaceutical companies.

Multiple Fragment Docking and Linking in Primary and Secondary Pockets of Dopamine Receptors
Gyorgy Keseru, Scientific Advisor, Hungarian Academy of Sciences, Hungary

We developed a powerful computational methodology for the identification of highy affinity and subtype selective class A GPCR ligands. Its usefulness is demonstrated designing potent and selective dopamine D3 receptor ligands.

Development of Chemical Probes for Studying Cancer
John Spencer, Professor, University of Sussex, United Kingdom

We will present the synthesis of privileged structure libraries and their applications against a range of biological targets.

Networking in Exhibition Hall

Profiling Non-Clinical Drug Development
Stella Stergiopoulos, Senior Project Manager, Tufts University School of Medicine, United States of America

The talk will open with a brief background on Tufts CSDD and our interest in non-clinical drug development. It will then talk about current trends in non-clinical development with respect to outsourcing.

Using Quantitative Systems Pharmacology for supporting rationally designed multi-target discovery projects in CNS R&D
Hugo Geerts, Chief Scientific Officer, In Silico Biosciences Inc, United States of America

Mechanistic Disease Modeling builds complex computer models from preclinical animal physiology and human pathology and is calibrated with clinical data. The approach can support rationally designed multi-target drug discovery programs and significantly de-risk therapeutic projects for complex CNS disorders.

Complementing Corporate Solutions with Simple Tools to Enhance Compound Management Workflows
Travis Mathewson, Principal Scientist, Pfizer Global Research and Development, United States of America

This talk will discuss the non-corporate tools and workflows integrated into compound management’s daily processes and the functions they support in order to ensure timely delivery of high quality products to better enable and streamline project screening efforts.